Table 1.
Baseline Characteristics of Experimental and Validation Cohorts Based on Responses or Results Reported on ACCESS Study Data Forms
| Experimental Cohort (n = 27) |
Validation Cohort (n = 29) |
||||||
|---|---|---|---|---|---|---|---|
| Controls n = 13 (48.15%) | Sarcoidosis Cases n = 14 (51.85%) | P value | Controls n = 12 (41.38%) | Sarcoidosis Cases n = 17 (58.62%) | P value | ||
| Ethnicity (%) | Caucasian | 13 (100) | 14 (100) | 1 | 12 (100) | 17 (100) | 1 |
| Sex (%) | Male | 6 (46.2) | 7 (50.0) | 1 | 4 (33.3) | 6 (35.3) | 1 |
| Female | 7 (53.8) | 7 (50.0) | 8 (66.7) | 11 (64.7) | |||
| Age (%) | <30 years | 1 (7.7) | 1 (7.1) | 0.886 | 1 (8.3) | 3 (17.6) | 0.822 |
| 30–39 years | 4 (30.8) | 5 (35.7) | 6 (50.0) | 6 (35.3) | |||
| 40–49 years | 6 (46.2) | 7 (50.0) | 3 (25.0) | 4 (23.5) | |||
| 50–59 years | 1 (7.7) | 0 (0.0) | 2 (16.7) | 3 (17.6) | |||
| 60–69 years | 1 (7.7) | 1 (7.1) | 0 (0.0) | 1 (5.9) | |||
| Smoking history (%) | Never | 7 (53.8) | 8 (57.1) | 1 | 5 (41.7) | 8 (47.1) | 1 |
| Positive | 6 (46.2) | 6 (42.9) | 7 (58.3) | 9 (52.9) | |||
| On treatment at time of inclusion (%) | No | — | 10 (71.4) | NA | — | 16 (94.1) | NA |
| Yes | — | 4 (28.6) | — | 1 (5.9) | |||
| Definite pulmonary involvement (%) | No | — | 2(14.3) | NA | — | 2 (11.8) | NA |
| Yes | — | 12 (85.7) | — | 15 (88.2) | |||
| Definite extrapulmonary involvement (%) | No | — | 7 (50.0) | NA | — | 9 (52.9) | NA |
| Yes | — | 7 (50.0) | — | 8 (47.1) | |||
| Definite pulmonary and extrapulmonary involvement (%) | No | — | 9 (64.3) | NA | — | 10 (58.8) | NA |
| Yes | — | 5 (35.7) | — | 7 (41.2) | |||
| Scadding stage on chest radiograph (%) | 0 | — | 4 (28.6) | NA | — | 3 (17.6) | NA |
| 1 | — | 5 (35.7) | — | 6 (35.3) | |||
| 2 | — | 5 (35.7) | — | 6 (35.3) | |||
| 3 | — | 0 (0) | — | 2 (11.8) | |||
| White blood cell count (, SD) | Absolute (K/ul) | — | 7.51 (3.39) | NA | — | 5.86 (1.68) | NA |
| PBMC (%) | — | 28.29 (9.34) | NA | — | 31.00 (7.83) | NA | |
| Lymphocyte (%) | — | 21.29 (9.27) | NA | — | 23.47 (7.90) | NA | |
| Baseline spirometry | FEV1 (% predicted) | — | 89.30 (8.54) | NA | — | 92.12 (16.70) | NA |
| FVC (% predicted) | — | 93.75 (10.49) | NA | — | 96.78 (17.03) | NA | |
| FEV1/FVC | — | 76.95 (9.51) | NA | — | 77.15 (6.32) | NA | |
Definition of abbreviations: ACCESS = A Case Controlled Etiologic Study of Sarcoidosis; NA = not applicable; PBMC = peripheral blood monocyte.
No parameter within or between the experimental and validation cohorts demonstrated a statistically significant difference by Student’s t test for continuous data or chi-square test for categorical data.